INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the membrane lining the joints (the synovium). Patients with RA may experience pain, redness, swelling, stiffness, and restricted movement around the joints of the hands, feet, elbows, knees, and neck that lead to loss of function, deformity, and disability. Approximately 1.5 million people in the US, or 0.6% of the population, have RA [1]. RA occurs 2-3 times more frequently in women than in men [2] . Although RA can affect people at any age, including children, onset usually occurs between 40 and 60 years of age [3] .
Current treatment options include medication, reduction of joint stress, occupational and physical therapy, and, in some cases, surgery. Pharmacologic treatments for RA generally fall into one of the three drug categories: nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs). Although the first two classes generally have a short onset of action, clinical response with DMARDs can take weeks to months [4] . Rheumatologists often use short courses of corticosteroids for acute flares of RA or as a bridge between other DMARDS, but the use of these drugs in RA is controversial [5] .
Although both NSAIDs and DMARDs help alleviate active RA symptoms, only DMARDs alter the progression of RA.
Worldwide, methotrexate (MTX) is a common first-line DMARD treatment for patients with RA. Early initiation of MTX in patients with RA helps manage joint destruction and slows disease progression [6] , and most patients who are prescribed MTX are still taking it after 5 years [7] . In patients with partial responses to MTX, additional treatments are often added. MTX can be combined safely with almost all other DMARDs approved for RA [4] . Although the long-term efficacy, tolerability, and safety of MTX have been well documented [6] , the clinical response to MTX treatment and the frequency of adverse events from the drug may impact patient adherence. Patient adherence can be influenced by duration of disease, disease activity, and medical comorbidities [8] . Better understanding of patterns of MTX use (as monotherapy and in combination therapy), patient and disease characteristics, adherence, and reasons for nonadherence may help in identifying patients who would benefit from alternative RA treatments and in devising strategies to increase overall patient adherence. Thus, the primary objectives of this study were to assess patients' self-reported adherence to MTX and to identify reasons for nonadherence.
METHODS

Study Design
The current study was a cross-sectional, The web-based questionnaire was selfadministered. Participants were encouraged to complete the questionnaire in a timely manner. Once they started the questionnaire, they were able to stop at any point and then resume it from that point. Participants who completed the questionnaire were not allowed to access the survey again.
Study Population
The survey participants were adults who met all the following criteria: self-reported physician diagnosis of RA, diagnosis of RA for at least 3 months, current use of MTX for at least 4 weeks, and ability to read and understand English and provide informed consent.
Eligible participants were classified into one of two groups based on their current MTX use: MTX monotherapy, currently taking MTX without any other prescription medications for RA; MTX combination therapy, currently taking MTX and at least one other prescription medication for RA. The target sample size for survey completion was 500 participants (250 per MTX group).
Questionnaire Content
The survey questionnaire assessed the following areas:
• demographic characteristics and health insurance information;
• current use of MTX and other prescription medications for RA;
• formulation, frequency of use, and dose of MTX;
• MTX adherence and reasons for nonadherence;
• satisfaction with MTX treatment; 
RESULTS
The screening portion of the survey questionnaire was completed by 3,849 RA panelists. In total, 596 participants (15%) met all eligibility criteria and were classified into 1 of the MTX groups. Of the 512 eligible participants who provided informed consent, 501 completed the questionnaire (251 in the MTX monotherapy group, 250 in the MTX combination therapy group; Fig. 1 ). Figure 1 depicts the passage of participants from screening to enrollment.
Demographics and Medical Comorbidities
Overall, study participants were predominantly female (62%), white (71%), and non-Hispanic (84%); 79% reported at least some college education. Nearly half the study participants (48%) were 18-44 years of age, and 30% were 45-54 years of age (Table 1) . Nearly half (47%)
reported 1 or more of the medical comorbidities assessed ( 
Methotrexate Adherence
Forty-two percent of the overall sample indicated that they did not take MTX exactly as prescribed by their doctors at all times during the past 4 weeks (Table 3) .
Of the 211 respondents who indicated that they did not always take MTX exactly as prescribed by their doctors, the most commonly reported reasons were forgetting to take it, feeling it was not needed when they felt well, and concern about the long-term safety of MTX (Fig. 2) . Forgetting to take MTX as prescribed was more frequently reported in MTX combination therapy (40%) than MTX monotherapy (27%) respondents (Pearson Chisquare test, P = 0.0361). Taking ''too many other medications'' was reported more frequently in the MTX combination group than the MTX monotherapy group (17 vs. 7%; P = 0.0362). Additionally, more than half the 211 respondents who indicated that they did not always take their MTX exactly as prescribed by their doctors reported that they took smaller doses than prescribed (53%) or skipped doses (52%), with similar patterns across MTX groups.
A logistic regression model was used to identify factors associated with level of MTX adherence (most or all of the time vs. none to some of the time). As shown in Fig. 3 
DISCUSSION
The primary objective of this cross-sectional, web-based survey study was to gain better understanding of adherence to MTX therapy and reasons for nonadherence. Better understanding of the profile of adherence and reasons for nonadherence may help identify strategies that can improve patient adherence and, ultimately, disease management.
In the current study, more than half the survey respondents were relatively ''new'' MTX users (less than 1 year), and 84% had been using MTX for fewer than 5 years. Although the sample size for those reporting MTX use of 5 years or more was relatively small, a larger percentage of MTX combination therapy than monotherapy patients reported longer-term use (5 years or more). This finding is not surprising given that most patients who are prescribed MTX are still taking it after 5 years, and additional treatments are often added for patients with partial responses to MTX [4] .
Patients likely have to be taking MTX for some time with limited success before another medication is added.
Nearly half the patients in the current study reported less than perfect adherence to MTX; similar results were seen across MTX groups. The most frequently reported reasons for nonadherence to MTX included forgetting or not remembering to take it, thinking it was not needed when they felt well, and concern about the long-term safety of MTX. More than half the MHAQ Modified Health Assessment Questionnaire, MTX methotrexate, SD standard deviation a The sum of the percentages exceeds 100% because respondents were allowed to select more than 1 response b MHAQ total score \0.3 suggests no disability Other 6 (6) 7 (7) 13 (6) No answer 0 0 0
MTX methotrexate a The sum of the percentages exceeds 100% because respondents were allowed to select more than 1 response Thus, it is not known how generalizable these findings are to the broader MTX population, particularly those who are less educated, sicker, and perhaps more disabled or more vulnerable (e.g., those of lower socioeconomic status).
Efforts to include these populations in future studies, such as in paper-and/or telephoneadministered surveys or recruitment through clinics, may aid in better understanding adherence in these patient populations.
Additionally, the participants recruited for this study came from a convenience sample of an existing RA panel who agreed to take healthrelated surveys as part of their panel participation. Thus, it is possible that, but Jennie Best is an employee of Genentech, Inc., and owns stock options.
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